These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Albrecht H; Denardo GL; Denardo SJ Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275 [TBL] [Abstract][Full Text] [Related]
24. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788 [TBL] [Abstract][Full Text] [Related]
25. Status of radioimmunotherapy in the new millennium. Imam SK Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488 [TBL] [Abstract][Full Text] [Related]
26. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control. Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279 [TBL] [Abstract][Full Text] [Related]
27. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934 [TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. Reilly RM J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623 [No Abstract] [Full Text] [Related]
38. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model. Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949 [TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods. Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127 [TBL] [Abstract][Full Text] [Related]
40. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]